Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb from an estimated USD 34.8 billion in 2025 to USD 53.6 billion by 2035. This ...

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

The S&P 500 added 0.8% on Friday, Aug. 8, 2025, finishing just short of the closing record it set last week. Gilead Sciences ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...